Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 701-705

  Burger, D M ^a   Van Rossum, A M C ^a   Hugen, P W H ^a   Suur, M H ^a   Hartwig, N G ^a   Geelen, S P M ^a   Scherpbier, H J ^a   Hoetelmans, R M W ^a   Vulto, A G ^a   De Groot, R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MULTICENTER STUDY; NETHERLANDS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE; VIRUS LOAD;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; INFANT; MALE; PROSPECTIVE STUDIES;

EID: 0035111835     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.701-705.2001     Document Type: Article

References (17)

1. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography
2. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
3. Pharmacokinetics of anti-infective agents in paediatric patients
4. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
5. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
6. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
7. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddl) in children infected with human immunodeficiency virus
8. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations
9. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs
10. Clinical, virological and immunological responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors
11. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: Preliminary, experience
12. A phase I/II study of the protease inhibitor indinavir in children with HIV infection
13. Protease inhibitor therapy in children with perinatally acquired HIV infection
14. A 24-week open-label phase I/II evaluation of the HIV-protease inhibitor MK-39 (indinavir)
15. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicentre study in the Netherlands
16. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus